Filtered By:
Condition: Atrial Fibrillation
Countries: Japan Health
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 333 results found since Jan 2013.
Association of Lower Urinary Tract Symptoms Based on the International Prostate Symptom Score and Cardiovascular Disease
CONCLUSIONS: The severity of LUTS was associated with a higher prevalence of CVD, especially CAD and stroke, independent of conventional CVD risk factors.PMID:34219077 | DOI:10.1253/circj.CJ-21-0278
Source: Circulation Journal - July 5, 2021 Category: Cardiology Authors: Yoshihiro Tanaka Satoko Matsuyama Hayato Tada Kenshi Hayashi Masayuki Takamura Masa-Aki Kawashiri Rod Passman Philip Greenland Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cost-Effectiveness Analysis of Percutaneous Patent Foramen Ovale Closure Preventing Secondary Ischemic Stroke in Japan
Cryptogenic ischemic stroke is a type of ischemic stroke for which the mechanism of onset and etiology cannot be explained or specified by any known mechanisms/factors. The possible involvement of patent foramen ovale (PFO) in the etiology of cryptogenic ischemic stroke has been reported.1 It was previously reported that occult atrial fibrillation and PFO were embolic sources that caused cryptogenic ischemic stroke.2 PFO is an opening formed during the course of fetal atrial septum development. Usually, it closes spontaneously after birth; however, PFO remains patent after maturation to adulthood.
Source: Journal of Stroke and Cerebrovascular Diseases - June 18, 2021 Category: Neurology Authors: Sachie Inoue, Ataru Igarashi, Yasuyuki Iguchi, Teiji Akagi Source Type: research
Characteristics and clinical outcomes in atrial fibrillation patients classified using cluster analysis: the Fushimi AF Registry
ConclusionsWe identified six clinically relevant phenotypes of AF patients on cluster analysis. These phenotypes can be associated with various types of comorbidities and associated with the incidence of clinical outcomes.Clinical Trial Registration Informationhttps://www.umin.ac.jp/ctr/index.htm. Unique identifier: UMIN000005834.
Source: Europace - April 30, 2021 Category: Cardiology Source Type: research
Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news
Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban —J-ELD AF Registry Subanalysis
ConclusionsThe incidence of events in each body weight group was comparable for stroke or systemic embolism and bleeding requiring hospitalization, and body weight<50 kg might not be an independent risk for death in Japanese non-valvular AF patients aged ≥ 75 years taking on-label doses of apixaban.
Source: Cardiovascular Drugs and Therapy - April 8, 2021 Category: Cardiology Source Type: research
Effectiveness and Safety of Rivaroxaban by General Practitioners - A Multicenter, Prospective Study in Japanese Patients With Non-Valvular Atrial Fibrillation (GENERAL)
CONCLUSIONS: The low incidence of adverse events, including stroke/SE and bleeding, in patients prescribed rivaroxaban by general practitioners supports its use as a safe and efficacious treatment in the standard clinical care of high-risk patient populations.PMID:33814525 | DOI:10.1253/circj.CJ-20-1244
Source: Circulation Journal - April 5, 2021 Category: Cardiology Authors: Kengo Kusano Nobuyoshi Sugishita Masaharu Akao Hikari Tsuji Kunihiko Matsui Shinya Hiramitsu Yutaka Hatori Hironori Odakura Hiroyuki Kamada Koji Miyamoto Hisao Ogawa Source Type: research
A Novel Risk Stratification System for Ischemic Stroke in Japanese Patients With Non-Valvular Atrial Fibrillation
CONCLUSIONS: The HELT-E2S2score may be useful for identifying Japanese NVAF patients at risk of ischemic stroke.PMID:33762526 | DOI:10.1253/circj.CJ-20-1075
Source: Circulation Journal - March 25, 2021 Category: Cardiology Authors: Ken Okumura Hirofumi Tomita Michikazu Nakai Eitaro Kodani Masaharu Akao Shinya Suzuki Kenshi Hayashi Mitsuaki Sawano Masahiko Goya Takeshi Yamashita Keiichi Fukuda Hisashi Ogawa Toyonobu Tsuda Mitsuaki Isobe Kazunori Toyoda Yoshihiro Miyamoto Hiroaki Miya Source Type: research
Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study
We examined 6806 patients whose baseline CrCl data were available and classified them into 2 groups: normal renal function group with CrCl ≥ 50 mL/min (n = 5326, 78%) and renal dysfunction group with CrCl < 50 mL/min (n = 1480, 22%). In the normal renal function group, 1609 (30%) received 10 mg/day (under-dose), while in the renal dysfunction group, 108 (7%) received 15 mg/day (over-dose). In the normal renal function group, under-dose of rivaroxaban was associated with higher all-cause mortality, while in t he renal dysfunction group, over-dose was associated with higher incidence of major bleed...
Source: Heart and Vessels - March 16, 2021 Category: Cardiology Source Type: research
